Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 34 clinical trials
Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma

The aim of the trial is to improve disease control after an allogeneic stem cell transplantation (alloSCT) for relapsed or refractory classical Hodgkin lymphoma (rrHL, cHL) with consolidation therapy by Brentuximab Vedotin (BV) for up to one year. The primary objective of the trial is to show efficacy of the …

  • 0 views
  • 26 Jan, 2021
  • 1 location
Abscopal Effect of Radiotherapy and Nivolumab in Relapsed Hodgkin Lymphoma After Anti-PD1 Therapy (AERN)

The aim of the trial is to improve efficacy of nivolumab in patients with relapsed or refractory HL who recently progressed on anti-PD1 therapy. Nivolumab is highly effective and well tolerated

avid
nivolumab
lymphoma
  • 4 views
  • 04 Oct, 2022
  • 1 location
Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL

This study is looking at the effects of Ipilimumab when it is given alone or in combination with Nivolumab to patients with relapsed or refractory classic Hodgkin's lymphoma (cHL). The names of the study drugs involved in this study are: Ipilimumab Nivolumab

measurable disease
cell transplantation
lymphoma
nivolumab
  • 0 views
  • 30 Apr, 2022
  • 3 locations
Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma

This study focuses on using shortened courses of radiation for participants with relapsed/refractory Hodgkin/Non-Hodgkin lymphoma. Treatment radiation over 5-6 weeks is often standard of care

lymphoma
  • 0 views
  • 24 Dec, 2021
  • 1 location
Brentuximab Vedotin Plus DHAP in Relapsed or Refractory Hodgkin's Lymphoma

< STUDY DESIGN > This study is a multi-center phase II trial in patients with relapsed or refractory Hodgkin's lymphoma after first-line treatment. < Treatment Schedule >

  • 0 views
  • 24 Mar, 2022
ANIMATE: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma (ANIMATE)

This is a single-arm, phase II, multi-centre study of the safety and efficacy of the PD-1 inhibitor, nivolumab, as second-line or third-line salvage therapy as a bridge to stem cell transplant (SCT) in relapsed/ refractory classical Hodgkin lymphoma patients not achieving a complete metabolic response (CMR) on FDG-PET-CT scan after …

brentuximab
pd-1 inhibitor
refractory hodgkin lymphoma
refractory classical hodgkin lymphoma
cell transplantation
  • 3 views
  • 12 May, 2022
  • 9 locations
Camrelizumab(SHR-1210) Combined With GEMOX in Patients With Relapsed or Refractory Hodgkin Lymphoma

This is an open-label, single arm, Phase 2 study to evaluate efficacy and safety of PD1 inhibitor Camrelizumab(SHR-1210) combined with Gemox in patients with relapsed and refractory hodgkin

chemotherapy regimen
pd-1 inhibitor
refractory hodgkin lymphoma
cell transplantation
lymphoma
  • 0 views
  • 24 Feb, 2022
SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma

This is a two-stage, Phase II clinical trial for patients with relapsed or refractory Hodgkin Lymphoma. The purpose of stage I is to evaluate whether treatment with the study drug decitabine in

refractory hodgkin lymphoma
cell transplantation
lymphoma
chemotherapy regimen
  • 3 views
  • 22 Jan, 2021
  • 1 location
CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma.

, interventional, single arm, open label, treatment study to evaluate the safety, tolerability and efficacy of HSP-CAR30 in patients with relapsed/refractory Hodgkin lymphoma and relapsed/refractory T-cell

  • 0 views
  • 27 Jan, 2021
  • 1 location
Phase II Study of Second-line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

The purpose of this study is to test any good and bad effects of the study drug, pembrolizumab, in combination with GVD in the treatment of Hodgkin lymphoma.

carbon monoxide
measurable disease
refractory hodgkin lymphoma
lymphoma
doxorubicin
  • 62 views
  • 20 Oct, 2022
  • 8 locations